Menu
Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy
Blood and Lymphatic Cancer: Targets and Therapy
ISSN: 1179-9889
- View all (103)
- Volume 14, 2024 (2)
- Volume 13, 2023 (7)
- Volume 12, 2022 (12)
- Volume 11, 2021 (6)
- Volume 10, 2020 (2)
- Volume 9, 2019 (7)
- Volume 8, 2018 (7)
- Volume 7, 2017 (8)
- Volume 6, 2016 (5)
- Volume 5, 2015 (11)
- Volume 4, 2014 (13)
- Volume 3, 2013 (6)
- Volume 2, 2012 (12)
- Volume 1, 2011 (5)
Journal Articles:
- 103 records -
AC024896.1/miR-363-3p Axis Regulates the Malignant Progression of Acute Myeloid Leukemia by Cuproptosis-Related Gene MYO1B
Zhang J, Zheng Y, Liu H, Liu B
Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:17-30
Published Date: 24 March 2024
Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies
Malfona F, Testi AM, Chiaretti S, Moleti ML
Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:1-15
Published Date: 13 March 2024
Polycythemia Vera: Barriers to and Strategies for Optimal Management
Duminuco A, Harrington P, Harrison C, Curto-Garcia N
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:77-90
Published Date: 21 December 2023
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
Alsuhebany N, Pan C, Holovac E, Do B, McBride A
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:67-76
Published Date: 24 November 2023
90Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases
Wang J, Baidoun F, Tun HW, Alhaj Moustafa M
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:59-65
Published Date: 3 October 2023
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
Hussain M, Yellapragada S, Al Hadidi S
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:33-57
Published Date: 15 September 2023
Successful Anatomy Adapted Therapeutic Management and Genetic Profiling of Primary Pituitary Diffuse Large B-Cell Lymphoma
Kimbrough EO, Gupta V, Jiang L, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:25-32
Published Date: 28 July 2023
Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma
Gessese T, Asrie F, Mulatie Z
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:13-24
Published Date: 29 May 2023
PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
Bou Zeid N, Yazbeck V
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:1-12
Published Date: 8 March 2023
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
Blackmon A, Aldoss I, Ball BJ
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:137-147
Published Date: 6 September 2022
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo MJ, Joseph JJ, Phan LM, DeStefano CB
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:119-136
Published Date: 29 August 2022
Differential Diagnosis of Waldenström’s Macroglobulinemia and Early Management: Perspectives from Clinical Practice
Cingam S, Sidana S
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:107-117
Published Date: 18 August 2022
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
Chung C
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:99-106
Published Date: 4 August 2022
Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
St-Pierre F, Ma S
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:81-98
Published Date: 22 July 2022
Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy
Juluri KR, Siu C, Cassaday RD
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:55-79
Published Date: 30 May 2022
Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy
Wang J, Alhaj Moustafa M, Kuhlman JJ, Seegobin K, Jiang L, Gupta V, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:47-54
Published Date: 25 May 2022
HIV/AIDS Associated Lymphoma: Review
Berhan A, Bayleyegn B, Getaneh Z
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:31-45
Published Date: 29 April 2022
Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
Kuhlman JJ, Alhaj Moustafa M, Jiang L, Wang J, Gupta V, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:23-29
Published Date: 14 April 2022
Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation
Kase AM, Bullock C, Parrondo R, Alhaj Moustafa M, Iqbal M, Li KD, Parent EE, Tun H
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:17-21
Published Date: 23 March 2022
Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
Hein K, Short N, Jabbour E, Yilmaz M
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:7-16
Published Date: 19 March 2022
How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice
Guru Murthy GS
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:1-6
Published Date: 19 March 2022
Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission
Seegobin K, Alhaj Moustafa M, Jiang L, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:67-72
Published Date: 22 September 2021
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
Pongas G, Cheson B
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:55-66
Published Date: 30 July 2021
Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
Stemer G, Rowe JM, Ofran Y
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:41-54
Published Date: 22 June 2021
Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review
Bender C, Maese L, Carter-Febres M, Verma A
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:25-40
Published Date: 19 April 2021
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
Gupta VA, Ackley J, Kaufman JL, Boise LH
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:11-24
Published Date: 12 March 2021
The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study
Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:1-9
Published Date: 22 January 2021
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Sigmund AM, Sahasrabudhe KD, Bhatnagar B
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:7-20
Published Date: 3 November 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:1-5
Published Date: 24 August 2020
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Lai C, Kandahari AM, Ujjani C
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:63-71
Published Date: 9 December 2019
Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1
Narimani M, Sharifi M, Jalili A
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:53-61
Published Date: 27 November 2019
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
Carrà G, Cartellà A, Maffeo B, Morotti A
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:45-52
Published Date: 6 November 2019
Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Kong F, Ren L, Zhang M
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:33-43
Published Date: 19 August 2019
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:19-32
Published Date: 27 June 2019
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
Schieber M, Ma S
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:9-17
Published Date: 12 March 2019
Strategies for minimal residual disease detection: current perspectives
Andreani G, Cilloni D
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:1-8
Published Date: 12 February 2019
Plasmablastic lymphoma: current perspectives
Lopez A, Abrisqueta P
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:63-70
Published Date: 4 October 2018
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
Hefazi M, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:47-61
Published Date: 25 September 2018
Current understanding of the role and regulation of miRNAs in Burkitt lymphoma
Videtta AD, Malagnino V, De Falco G
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:33-45
Published Date: 11 May 2018
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
Blum A, Bazou D, O'Gorman P
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:21-31
Published Date: 20 April 2018
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
Lapuz C, Enjeti AK, O'Brien PC, Capp AL, Holliday EG, Gupta SA
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:13-20
Published Date: 18 April 2018
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Anagnostou T, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:11-12
Published Date: 11 April 2018
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
Anagnostou T, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:1-9
Published Date: 22 December 2017
Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
Trottier AM, Cerquozzi S, Owen CJ
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:85-93
Published Date: 11 December 2017
Impact of obinutuzumab alone and in combination for follicular lymphoma
Sarraf Yazdy M, Cheson BD
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:73-83
Published Date: 19 October 2017
Complications and management of coagulation disorders in leukemia patients
Lad DP, Jain A, Varma S
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:61-72
Published Date: 18 September 2017
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
Bhutani D, Zonder JA
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:53-60
Published Date: 19 July 2017
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
Karantanos T, Politikos I, Boussiotis VA
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:37-52
Published Date: 9 May 2017
Clinical potential of midostaurin in advanced systemic mastocytosis
Chandesris MO, Damaj G, Lortholary O, Hermine O
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:25-35
Published Date: 3 May 2017
Uptake of lymphoma-derived exosomes by peripheral blood leukocytes
Ferguson Bennit HR, Gonda A, Oppegard LJ, Chi DP, Khan S, Wall NR
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:9-23
Published Date: 28 February 2017